Mike,
Sorry for the late response. I understand in discussions with my Dad over the past few months that BIOHF has the best (to date) solution to the Diabetes II insulin-sensitizing drug issue. Currently, Warner- Lambert and SmithKline Beecham are selling their own versions of insulin-sensitizing drugs which are primarily made up of the "glitazone" chemical family, WLA (Resulin) and SMH (Avandia). WLA first came on the scene with Resulin, however, they are now starting to see MAJOR side-effects and worse yet high-toxcity causing problems for the liver causing death in some patients. SMH then came out with a modified version of Resulin called Avandia, same chemical make-up primarily so that they could get quick FDA approval in the US. Big mistake, basically same problems as WLA has now. BIOHF on the other hand has a different chemical make-up, to date in international testing (Argentina, China, Brazil) with few if any problems. Bottom line a better solution, however, no FDA approval yet, but in 1-2 years at the most they will be the leader in this area in the USA. I predict $50-100 stock in 2 years, IF all goes well.
Get in, or be sorry,
Rich |
